Phase I study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

• Jennifer R. Brown,
• Wael A. Harb,
• Brian T. Hill,
• Janice Gabrilove,
• Jeff P. Sharman,
• Marshall T. Schreeder,
• Paul M. Barr,
• James M. Foran,
• Thomas P. Miller,
• Jan A. Burger,
• Kevin R. Kelly,
• Daruka Mahadevan,
• Shuo Ma,
• Yan Li,
• Daniel W. Pierce,
• Evelyn Barnett,
• Jeffrey Marine,
• Monika Miranda,
• Ada Azaryan,
• Xujie Yu,
• Pilar Nava-Parada,
• Jay Mei,
• Thomas J. Kipps

Affiliations

Jennifer R. Brown

Dana-Farber Cancer Institute, Boston, MA, USA

Wael A. Harb

Horizon Oncology Center, Lafayette, IN, USA

Brian T. Hill

Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA

Janice Gabrilove

Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Jeff P. Sharman

Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA

Marshall T. Schreeder

Clearview Cancer Institute, Huntsville, AL, USA

Paul M. Barr

Hematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA

James M. Foran

Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA

Thomas P. Miller

University of Arizona Cancer Center, Tucson, AZ, USA

Jan A. Burger

Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA

Kevin R. Kelly

University of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA

Daruka Mahadevan

The West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA

Shuo Ma

Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

Yan Li

Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA

Daniel W. Pierce

Department of Translational Medicine, Celgene Corporation, San Francisco, CA, USA

Evelyn Barnett

Celgene Corporation, Summit, NJ, USA

Jeffrey Marine

Celgene Corporation, Summit, NJ, USA

Monika Miranda

Celgene Corporation, Summit, NJ, USA

Ada Azaryan

Celgene Corporation, Berkeley Heights, NJ, USA

Xujie Yu

Celgene Corporation, Berkeley Heights, NJ, USA

Pilar Nava-Parada

Celgene Corporation, Summit, NJ, USA

Jay Mei

Celgene Corporation, Summit, NJ, USA

Thomas J. Kipps

University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA